136 related articles for article (PubMed ID: 25387885)
21. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints.
Rauch GM; Kuerer HM; Adrada B; Santiago L; Moseley T; Candelaria RP; Arribas E; Sun J; Leung JWT; Krishnamurthy S; Yang WT
Ann Surg Oncol; 2018 Jul; 25(7):1953-1960. PubMed ID: 29667115
[TBL] [Abstract][Full Text] [Related]
22. Pathological complete response in neoadjuvant treatment of breast cancer.
Cortazar P; Geyer CE
Ann Surg Oncol; 2015 May; 22(5):1441-6. PubMed ID: 25727556
[TBL] [Abstract][Full Text] [Related]
23. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of evaluating tumor vascularization using 3D power Doppler ultrasound with high-definition flow technology in the prediction of the response to neoadjuvant chemotherapy for T2 breast cancer: a preliminary report.
Shia WC; Chen DR; Huang YL; Wu HK; Kuo SJ
Phys Med Biol; 2015 Oct; 60(19):7763-78. PubMed ID: 26393306
[TBL] [Abstract][Full Text] [Related]
25. Using Flow Characteristics in Three-Dimensional Power Doppler Ultrasound Imaging to Predict Complete Responses in Patients Undergoing Neoadjuvant Chemotherapy.
Shia WC; Huang YL; Wu HK; Chen DR
J Ultrasound Med; 2017 May; 36(5):887-900. PubMed ID: 28109009
[TBL] [Abstract][Full Text] [Related]
26. Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
Bufi E; Belli P; Costantini M; Cipriani A; Di Matteo M; Bonatesta A; Franceschini G; Terribile D; Mulé A; Nardone L; Bonomo L
Clin Breast Cancer; 2015 Oct; 15(5):370-80. PubMed ID: 25891905
[TBL] [Abstract][Full Text] [Related]
27. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
Keam B; Im SA; Lim Y; Han SW; Moon HG; Oh DY; Cho N; Lee SH; Han W; Moon WK; Kim DW; Kim TY; Park IA; Noh DY
Ann Surg Oncol; 2013 Jul; 20(7):2242-9. PubMed ID: 23529780
[TBL] [Abstract][Full Text] [Related]
28. MRI volume measurements compared with the RECIST 1.1 for evaluating the response to neoadjuvant chemotherapy for mass-type lesions.
An YY; Kim SH; Kang BJ; Lee AW; Song BJ
Breast Cancer; 2014 May; 21(3):316-24. PubMed ID: 22767314
[TBL] [Abstract][Full Text] [Related]
29. [Characterization of sonographically detected breast lesions using three-dimensional data sets].
Fischer T; Filimonow S; Hamm B; Slowinski T; Thomas A
Rofo; 2006 Dec; 178(12):1224-34. PubMed ID: 17136646
[TBL] [Abstract][Full Text] [Related]
30. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
Park S; Yoon JH; Sohn J; Park HS; Moon HJ; Kim MJ; Kim EK; Kim SI; Park BW
PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.
Gounaris I; Provenzano E; Vallier AL; Hiller L; Iddawela M; Hilborne S; Taylor K; Britton P; Earl HM; Sinnatamby R
Breast Cancer Res Treat; 2011 Jun; 127(2):459-69. PubMed ID: 21437610
[TBL] [Abstract][Full Text] [Related]
32. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
33. Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS.
Shin HJ; Baek HM; Ahn JH; Baek S; Kim H; Cha JH; Kim HH
NMR Biomed; 2012 Dec; 25(12):1349-59. PubMed ID: 22566277
[TBL] [Abstract][Full Text] [Related]
34. Ultrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers: Recent Progress.
Xu C; Vavadi H; Merkulov A; Li H; Erfanzadeh M; Mostafa A; Gong Y; Salehi H; Tannenbaum S; Zhu Q
Ultrason Imaging; 2016 Jan; 38(1):5-18. PubMed ID: 25887527
[TBL] [Abstract][Full Text] [Related]
35. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):552-62. PubMed ID: 18398094
[TBL] [Abstract][Full Text] [Related]
36. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
Jung SY; Kim SK; Nam BH; Min SY; Lee SJ; Park C; Kwon Y; Kim EA; Ko KL; Park IH; Lee KS; Shin KH; Lee S; Kim SW; Kang HS; Ro J
Ann Surg Oncol; 2010 Jan; 17(1):247-53. PubMed ID: 19777177
[TBL] [Abstract][Full Text] [Related]
39. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
